I
33.50
0.09 (0.27%)
| Previous Close | 33.41 |
| Open | 33.20 |
| Volume | 1,998,708 |
| Avg. Volume (3M) | 1,787,256 |
| Market Cap | 6,877,848,576 |
| Price / Book | 8.02 |
| 52 Weeks Range | |
| Earnings Date | 10 Aug 2026 |
| Diluted EPS (TTM) | -2.73 |
| Total Debt/Equity (MRQ) | 0.01% |
| Current Ratio (MRQ) | 11.16 |
| Operating Cash Flow (TTM) | -375.87 M |
| Levered Free Cash Flow (TTM) | -227.82 M |
| Return on Assets (TTM) | -37.97% |
| Return on Equity (TTM) | -62.46% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Immunovant, Inc. | Bullish | Bearish |
AIStockmoo Score
-0.4
| Analyst Consensus | 2.0 |
| Insider Activity | -2.5 |
| Price Volatility | -3.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.5 |
| Average | -0.40 |
|
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 58.17% |
| % Held by Institutions | 55.78% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| FROMKIN ANDREW J. | - | 33.50 | -221,951 | -7,435,359 |
| Aggregate Net Quantity | -221,951 | |||
| Aggregate Net Value ($) | -7,435,359 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 33.50 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| FROMKIN ANDREW J. | Director | 28 May 2026 | Sell (-) | 221,951 | 33.50 | 7,435,359 |
| FROMKIN ANDREW J. | Director | 28 May 2026 | Option execute | 196,601 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |